Avoralstat for Diabetic Macular Edema

This trial tests a new treatment called avoralstat to determine its safety and effectiveness for people with diabetic macular edema (DME), a condition that causes eye swelling and can lead to vision problems. The study involves a one-time injection of avoralstat directly into the eye. Suitable candidates for this trial have DME with vision issues requiring treatment and have not received more than three anti-VEGF injections. The researchers aim to find a new way to help people with DME maintain or improve their vision. As a Phase 1 trial, this research focuses on understanding how avoralstat works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. However, if you have started new diabetes medications within the last 3 months, you may not be eligible to participate.

Research shows that avoralstat is being tested for its safety and potential to help with diabetic macular edema (DME), an eye condition. In this study, participants received a single dose of avoralstat, and researchers closely monitor its safety. Previous studies suggest that avoralstat is generally well-tolerated, with no major safety concerns reported so far. However, since this is an early study, the main goal is to ensure the treatment is safe for people with DME. Participants might help identify any side effects not yet noticed.¹²³⁴⁵

Unlike the standard treatments for diabetic macular edema, which often involve anti-VEGF injections or corticosteroids, Avoralstat offers a novel approach. Avoralstat is administered as a single dose through a suprachoroidal injection, which directly targets the back of the eye and may enhance drug delivery efficiency. Researchers are excited about Avoralstat because it has the potential to reduce inflammation by specifically inhibiting kallikrein, a different mechanism than current options, which might lead to improved outcomes and fewer side effects.

Research has shown that avoralstat, administered as a single-dose suprachoroidal injection in this trial, might help treat diabetic macular edema (DME), a condition where fluid leaks into the retina and causes vision problems. Studies in rabbits demonstrated that avoralstat can stop this fluid from leaking. This finding is promising because it suggests the drug might help keep the retina dry and improve vision in humans. Avoralstat is known for its effectiveness, meaning it can work well even in small doses. While more studies are needed in people, these early findings are encouraging.¹²³⁴⁵